Loading...
•
Dec 31, 2019
Equillium Q4 2019 Earnings Report
Equillium reported financial results for Q4 2019, including a net loss of $7.6 million and provided a business update, pausing the EQUIP and EQUALISE studies due to the COVID-19 pandemic while reaffirming guidance for initial data from the EQUATE trial in 2H 2020.
Key Takeaways
Equillium announced its Q4 2019 financial results, highlighted by a net loss of $7.6 million. The company paused enrollment in the EQUIP and EQUALISE trials due to the COVID-19 pandemic but maintained its guidance for initial data from the EQUATE trial in the second half of 2020. They also reiterated that current cash is sufficient to fund operations into the second half of 2021.
Paused enrollment in EQUIP trial for uncontrolled asthma and EQUALISE trial for lupus nephritis due to COVID-19.
Reaffirmed guidance to report initial data from the EQUATE trial in acute GVHD in 2H 2020.
Cash on hand is sufficient to fund operations into the second half of 2021.
R&D expenses increased to $5.4 million, driven by clinical development activities.
Forward Guidance
Equillium anticipates reporting initial data from the EQUATE study during the second half of 2020 and believes that its cash on hand is sufficient to fund operations into the second half of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...